DK1745295T3 - Fremgangsmåder, sammensætninger og forbindelsesanalyser til hæmning af produktionen af amyloid beta-protein - Google Patents
Fremgangsmåder, sammensætninger og forbindelsesanalyser til hæmning af produktionen af amyloid beta-proteinInfo
- Publication number
- DK1745295T3 DK1745295T3 DK05744241.0T DK05744241T DK1745295T3 DK 1745295 T3 DK1745295 T3 DK 1745295T3 DK 05744241 T DK05744241 T DK 05744241T DK 1745295 T3 DK1745295 T3 DK 1745295T3
- Authority
- DK
- Denmark
- Prior art keywords
- amyloid
- production
- inhibit
- gpcr
- beta
- Prior art date
Links
- 102000013455 Amyloid beta-Peptides Human genes 0.000 title abstract 3
- 108010090849 Amyloid beta-Peptides Proteins 0.000 title abstract 3
- 150000001875 compounds Chemical class 0.000 title abstract 3
- 238000000034 method Methods 0.000 title abstract 3
- 238000003556 assay Methods 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 102000014303 Amyloid beta-Protein Precursor Human genes 0.000 abstract 2
- 108010079054 Amyloid beta-Protein Precursor Proteins 0.000 abstract 2
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 abstract 2
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 abstract 2
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 208000028698 Cognitive impairment Diseases 0.000 abstract 1
- 238000000423 cell based assay Methods 0.000 abstract 1
- 208000010877 cognitive disease Diseases 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 229920001184 polypeptide Polymers 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 230000020978 protein processing Effects 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
- C12Q1/37—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving peptidase or proteinase
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4709—Amyloid plaque core protein
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/72—Assays involving receptors, cell surface antigens or cell surface determinants for hormones
- G01N2333/726—G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
- G01N2800/2821—Alzheimer
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biotechnology (AREA)
- Analytical Chemistry (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Wood Science & Technology (AREA)
- Cell Biology (AREA)
- Zoology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Genetics & Genomics (AREA)
- General Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US56366104P | 2004-04-20 | 2004-04-20 | |
| PCT/EP2005/004325 WO2005103713A2 (en) | 2004-04-20 | 2005-04-20 | Methods, compositions and compound assays for inhibiting amyloid-beta protein production |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK1745295T3 true DK1745295T3 (da) | 2011-01-31 |
Family
ID=35197590
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK05744241.0T DK1745295T3 (da) | 2004-04-20 | 2005-04-20 | Fremgangsmåder, sammensætninger og forbindelsesanalyser til hæmning af produktionen af amyloid beta-protein |
Country Status (10)
| Country | Link |
|---|---|
| US (3) | US7429459B2 (enExample) |
| EP (3) | EP1745295B1 (enExample) |
| JP (1) | JP4890442B2 (enExample) |
| AT (1) | ATE483981T1 (enExample) |
| CA (1) | CA2605574A1 (enExample) |
| DE (1) | DE602005023976D1 (enExample) |
| DK (1) | DK1745295T3 (enExample) |
| ES (1) | ES2353604T3 (enExample) |
| SI (1) | SI1745295T1 (enExample) |
| WO (1) | WO2005103713A2 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI1745295T1 (sl) * | 2004-04-20 | 2011-01-31 | Galapagos Nv | Metode, sestavljanje in preizkuĺ anje spojine za zaviranje tvorbe proteina amiloid-beta |
| WO2008088401A2 (en) * | 2006-09-13 | 2008-07-24 | The Trustees Of Columbia University In The City Of New York | Methods for identifying, or assaying for agents that increase beta-cell proliferation, insulin secretion, insulin sensitivity, glucose tolerance and decreases fat mass |
| GB0700645D0 (en) * | 2007-01-12 | 2007-02-21 | Eisai London Res Lab Ltd | Targets for disease therapy |
| US20090053140A1 (en) * | 2007-05-15 | 2009-02-26 | Roderick Euan Milne Scott | METHODS OF IDENTIFYING GENES INVOLVED IN MEMORY FORMATION USING SMALL INTERFERING RNA(siRNA) |
| AU2008254905A1 (en) * | 2007-05-15 | 2008-11-27 | Helicon Therapeutics, Inc. | Methods of treating cognitive disorders by inhibition of Gpr12 |
| JP5049713B2 (ja) * | 2007-09-14 | 2012-10-17 | 株式会社コナミデジタルエンタテインメント | ゲームシステム並びにこれを構成するゲーム装置及び課題報知装置 |
| WO2010142603A1 (en) * | 2009-06-08 | 2010-12-16 | Vib Vzw | Screening for compounds that modulate gpr3-mediated beta-arrestin signaling and amyloid beta peptide generation |
| US9757398B2 (en) | 2010-02-20 | 2017-09-12 | Euroespes Biotecnnologia, S.L. | Prevention and treatment of alzheimer's disease by amyloid beta peptide and sphin-gosine-1-phosphate |
| US20130331330A1 (en) * | 2012-06-08 | 2013-12-12 | The Board Of Trustees Of The Leland Stanford Junior University | Methods of treating alzheimer's disease and other tauopathies with inhibitors of microtubule affinity regulating kinase |
| US20150065376A1 (en) * | 2013-08-12 | 2015-03-05 | Holger Knaut | Expression constructs encoding g protein coupled receptors and methods of use thereof |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US5354844A (en) | 1989-03-16 | 1994-10-11 | Boehringer Ingelheim International Gmbh | Protein-polycation conjugates |
| US5693622A (en) | 1989-03-21 | 1997-12-02 | Vical Incorporated | Expression of exogenous polynucleotide sequences cardiac muscle of a mammal |
| US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
| US5264618A (en) | 1990-04-19 | 1993-11-23 | Vical, Inc. | Cationic lipids for intracellular delivery of biologically active molecules |
| EP0786522A2 (en) | 1992-07-17 | 1997-07-30 | Ribozyme Pharmaceuticals, Inc. | Enzymatic RNA molecules for treatment of stenotic conditions |
| FR2714830B1 (fr) | 1994-01-10 | 1996-03-22 | Rhone Poulenc Rorer Sa | Composition contenant des acides nucléiques, préparation et utilisations. |
| FR2715847B1 (fr) | 1994-02-08 | 1996-04-12 | Rhone Poulenc Rorer Sa | Composition contenant des acides nucléiques, préparation et utilisations. |
| FR2727679B1 (fr) | 1994-12-05 | 1997-01-03 | Rhone Poulenc Rorer Sa | Nouveaux agents de transfection et leurs applications pharmaceutiques |
| FR2730637B1 (fr) | 1995-02-17 | 1997-03-28 | Rhone Poulenc Rorer Sa | Composition pharmaceutique contenant des acides nucleiques, et ses utilisations |
| US6090575A (en) * | 1995-03-30 | 2000-07-18 | Human Genome Sciences, Inc. | Polynucleotides encoding human G-protein coupled receptor GPR1 |
| US5998164A (en) * | 1995-03-30 | 1999-12-07 | Human Genome Sciences, Inc. | Polynucleotides encoding human G-protein coupled receptor GPRZ |
| JPH11503012A (ja) * | 1995-03-30 | 1999-03-23 | ヒューマン ジノーム サイエンシーズ，インコーポレイテッド | ヒトｇタンパク質結合レセプター |
| US6653086B1 (en) * | 1998-04-14 | 2003-11-25 | Arena Pharmaceuticals, Inc. | Endogenous constitutively activated G protein-coupled orphan receptors |
| US6413776B1 (en) | 1998-06-12 | 2002-07-02 | Galapagos Geonomics N.V. | High throughput screening of gene function using adenoviral libraries for functional genomics applications |
| US6420563B1 (en) | 1998-07-31 | 2002-07-16 | Arena Pharmaceuticals, Inc. | Small molecule modulators of G protein-coupled receptor six |
| CN1364167A (zh) | 1999-02-26 | 2002-08-14 | 阿瑞那制药公司 | G蛋白偶联受体6的小分子调节剂 |
| EP1240199A2 (en) * | 1999-12-10 | 2002-09-18 | AstraZeneca AB | Method for screening of appetite control agents |
| AU2001250529A1 (en) * | 2000-05-03 | 2001-11-12 | Astrazeneca Ab | Use of the g protein coupled receptor gpr3 to identify appetite control agents |
| AU2001264967A1 (en) * | 2000-05-24 | 2001-12-03 | Genaissance Pharmaceuticals, Inc. | Haplotypes of the gpr3 gene |
| US7163800B2 (en) * | 2000-11-03 | 2007-01-16 | Molecular Devices Corporation | Methods of screening compositions for G protein-coupled receptor desensitization inhibitory activity |
| WO2002061087A2 (en) * | 2000-12-19 | 2002-08-08 | Lifespan Biosciences, Inc. | Antigenic peptides, such as for g protein-coupled receptors (gpcrs), antibodies thereto, and systems for identifying such antigenic peptides |
| WO2002068579A2 (en) | 2001-01-10 | 2002-09-06 | Pe Corporation (Ny) | Kits, such as nucleic acid arrays, comprising a majority of human exons or transcripts, for detecting expression and other uses thereof |
| US20030198627A1 (en) | 2001-09-01 | 2003-10-23 | Gert-Jan Arts | siRNA knockout assay method and constructs |
| WO2003071272A1 (en) * | 2002-02-22 | 2003-08-28 | Takeda Chemical Industries, Ltd. | Method of determining ligand |
| ATE420109T1 (de) * | 2002-05-13 | 2009-01-15 | Molecular Devices Corp | Konstitutiv translozierende zelllinie |
| JP4184875B2 (ja) * | 2002-06-14 | 2008-11-19 | 武田薬品工業株式会社 | 新規スクリーニング方法 |
| US20040023384A1 (en) * | 2002-07-31 | 2004-02-05 | Isis Pharmaceuticals Inc. | Antisense modulation of G protein-coupled receptor 12 expression |
| US20040023380A1 (en) * | 2002-07-31 | 2004-02-05 | Isis Pharmaceuticals Inc. | Antisense modulation of G protein-coupled receptor 6 expression |
| AU2003276106A1 (en) * | 2002-10-24 | 2004-05-13 | Bayer Healthcare Ag | Diagnostics and therapeutics for diseases associated with human g-protein coupled receptor 12 (gpr12) |
| AU2003301892A1 (en) * | 2002-11-04 | 2004-06-07 | Bayer Healthcare Ag | Diagnostics and therapeutics for diseases associated with human g-protein coupled receptor 3 (gpr3) |
| WO2004094636A1 (en) | 2003-04-24 | 2004-11-04 | Galapagos Genomics N.V. | Effective sirna knock-down constructs |
| CA2539127A1 (en) * | 2003-09-19 | 2005-03-31 | Paradigm Therapeutics Limited | Receptor |
| SI1745295T1 (sl) * | 2004-04-20 | 2011-01-31 | Galapagos Nv | Metode, sestavljanje in preizkuĺ anje spojine za zaviranje tvorbe proteina amiloid-beta |
-
2005
- 2005-04-20 SI SI200531166T patent/SI1745295T1/sl unknown
- 2005-04-20 DK DK05744241.0T patent/DK1745295T3/da active
- 2005-04-20 DE DE602005023976T patent/DE602005023976D1/de not_active Expired - Lifetime
- 2005-04-20 AT AT05744241T patent/ATE483981T1/de active
- 2005-04-20 CA CA002605574A patent/CA2605574A1/en not_active Abandoned
- 2005-04-20 EP EP05744241A patent/EP1745295B1/en not_active Expired - Lifetime
- 2005-04-20 WO PCT/EP2005/004325 patent/WO2005103713A2/en not_active Ceased
- 2005-04-20 JP JP2007508855A patent/JP4890442B2/ja not_active Expired - Fee Related
- 2005-04-20 ES ES05744241T patent/ES2353604T3/es not_active Expired - Lifetime
- 2005-04-20 EP EP10174529A patent/EP2270513A3/en not_active Withdrawn
- 2005-04-20 EP EP10174532A patent/EP2267458A3/en not_active Withdrawn
- 2005-04-20 US US11/110,274 patent/US7429459B2/en not_active Expired - Fee Related
-
2008
- 2008-08-13 US US12/190,888 patent/US7910320B2/en not_active Expired - Fee Related
-
2011
- 2011-02-01 US US13/019,057 patent/US20110118338A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| ATE483981T1 (de) | 2010-10-15 |
| EP2267458A2 (en) | 2010-12-29 |
| DE602005023976D1 (de) | 2010-11-18 |
| EP1745295A2 (en) | 2007-01-24 |
| US20090005262A1 (en) | 2009-01-01 |
| WO2005103713A3 (en) | 2006-09-08 |
| US7910320B2 (en) | 2011-03-22 |
| EP2270513A3 (en) | 2011-04-06 |
| JP2007533989A (ja) | 2007-11-22 |
| WO2005103713A2 (en) | 2005-11-03 |
| ES2353604T3 (es) | 2011-03-03 |
| CA2605574A1 (en) | 2005-11-03 |
| SI1745295T1 (sl) | 2011-01-31 |
| JP4890442B2 (ja) | 2012-03-07 |
| US20110118338A1 (en) | 2011-05-19 |
| HK1099810A1 (en) | 2007-08-24 |
| EP1745295B1 (en) | 2010-10-06 |
| US7429459B2 (en) | 2008-09-30 |
| EP2267458A3 (en) | 2011-04-06 |
| EP2270513A2 (en) | 2011-01-05 |
| US20050266502A1 (en) | 2005-12-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2005108949A3 (en) | Methods, compositions and compound assays for inhibiting amyloid-beta protein production | |
| CY1125427T1 (el) | Anti-gm-csf αντισωματα και χρησεις αυτων | |
| NO20072721L (no) | Polypeptides that bind BR3 and uses thereof | |
| DK2046951T5 (da) | Proteasesreeningsmetoder og proteaser identificeret dermed | |
| EA200901436A1 (ru) | Антигенсвязывающие белки, связывающие par-2 | |
| ATE472734T1 (de) | Direktbestimmung von vitamin d im serum oder plasma | |
| EA200901313A1 (ru) | Ингибиторы тирозинкиназы брутона | |
| ATE541054T1 (de) | Bio-barcode erkennung für zielmoleküle | |
| DK1745295T3 (da) | Fremgangsmåder, sammensætninger og forbindelsesanalyser til hæmning af produktionen af amyloid beta-protein | |
| US10119168B2 (en) | Methods for the treatment of kidney fibrosis | |
| DK2185937T3 (da) | Fremgangsmåde til at bestemme sepsis hos mennesker | |
| Tomar et al. | TRIM4; a novel mitochondrial interacting RING E3 ligase, sensitizes the cells to hydrogen peroxide (H2O2) induced cell death | |
| DE602006006855D1 (de) | Morbus alzheimer-spezifische veränderungen des erkheimer-spezifische molekulare biomarker (adsmb) | |
| DK2005190T4 (da) | Inhibering af GASC1 | |
| UA107789C2 (en) | Method based on biomarkers designed to monitor treatment | |
| WO2005119262A3 (en) | Methods, compositions and compound assays for inhibiting amyloid-beta protein production | |
| WO2006053251A3 (en) | Method of measuring amyloid-beta peptides | |
| WO2005103693A3 (en) | Methods, compositions and compound assays for inhibiting amyloid-beta protein production | |
| WO2007095378A3 (en) | Mass tagging for quantitative analysis of biomolecules using 13c labeled phenylisocyanate | |
| ATE504833T1 (de) | Verfahren zur bestimmung des phänotyps von zellen | |
| ATE353544T1 (de) | Verwendung des proteins masp als marker für kolorektale karzinome | |
| WO2005103715A3 (en) | Methods, compositions and compound assays for inhibiting amyloid-beta protein production | |
| ATE359516T1 (de) | Verwendung des proteins crabp ii (cellular retinoic acid-binding protein ii) als marker für brustkrebs | |
| NO20053990L (no) | Assay for proteinisoformer | |
| Chen et al. | Effect of Alanine Replacement of L17 and F19 on the Aggregation and Neurotoxicity of Arctic-Type Aβ40 |